CDER director on accelerated approval reforms and a court decision that will 'send a chill' across rare disease drug development

Zachary Brennan

Senior Editor

At the second of two hearings before the Senate Health, Education, Labor & Pensions Committee on the must-pass legislation (by the end of September) regarding …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

CDER director on accelerated approval reforms and a court decision that will 'send a chill' across rare disease drug development

Zachary Brennan

Senior Editor

Sign up to read this article for free.

Executive Director, Marketing

Celldex Therapeutics

Hampton, NJ, USA

Makary, in one of first comments on FDA policy, floats new pathway for rare disease drugs

China startup injects CRISPR therapy into the brain for the first time

Trodelvy and Keytruda combo succeeds in Phase 3 breast cancer study

Roivant brings rare disease program closer as Immunovant CEO retires

FDA plans to ban pharma employees from serving on adcomms. The impact will be limited

ADSTILADRIN® (nadofaragene firadenovec-vncg) – A Growing Body of Clinical Data and Real-World Evidence

CDER di­rec­tor on ac­cel­er­at­ed ap­proval re­forms and a court de­ci­sion that will 'send a chill' across rare dis­ease drug de­vel­op­ment

Senior Editor

Sign up to read this article for free.

Celldex Therapeutics

Hampton, NJ, USA

CDER director on accelerated approval reforms and a court decision that will 'send a chill' across rare disease drug development